Evidence map›Paper›PMID 37264762›Full record

SynthesisESC heart failure2023

Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: a systematic review and meta-analysis.

Anna Cantone, Matteo Serenelli, Federico Sanguettoli, Daniele Maio, Gioele Fabbri, Beatrice Dal Passo, Piergiuseppe Agostoni, Giovanni Grazzi, Gianluca Campo, Claudio Rapezzi

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. VOCurrent cardiology reports · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anna CantoneCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Matteo SerenelliCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.ORCID 0000-0002-8947-7176
Federico SanguettoliCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Daniele MaioCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Gioele FabbriCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Beatrice Dal PassoCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Piergiuseppe AgostoniCentro Cardiologico Monzino, IRCCS, Milan, Italy.
Giovanni GrazziCenter for Exercise Science and Sport, University of Ferrara, Ferrara, Italy.
Gianluca CampoCardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Claudio RapezziCardiovascular Institute, University of Ferrara, Ferrara, Italy.
Azienda Unità Sanitaria Locale di Ferrara · ITUniversity of Ferrara · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical value of cardiopulmonary exercise testing (CPET) in cardiac amyloidosis (CA) is uncertain. Due to the growing prevalence of the disease and the current availability of disease-modifying drugs, prognostic stratification is becoming fundamental to optimizing the cost-effectiveness of treatment, patient phenotyping, follow-up, and management. Peak VO METHODS AND

resultsWe performed a systematic review and searched for clinical studies performing CPET for prognostication in patients with transthyretin-CA and light-chain-CA. Studies reporting hazard ratio (HR) for mortality and peak VO

conclusionsCPET is a valuable tool for prognostic stratification in CA, identifying patients at increased risk of death. Large prospective clinical trials are needed to confirm this exploratory finding.

Indexed as

AmyloidosisCardiomyopathiesExercise TestHumansOxygen ConsumptionPrognosisProspective StudiesAmyloidosisCPETHeart failureMortalityVE/VCO slopeVO2 peak

Identifiers

PMID37264762
PMCPMC10375073
OpenAlexW4379095553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.